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As people age, chronic kidney disease becomes more common, but it rarely leads to end-stage 
kidney disease. When it does, the choice between dialysis and conservative care can be daunting, as 
much depends on life expectancy and personal expectations of medical care. Shared decision making 
implies adequately informing patients about their options, and facilitating deliberation of the avai-
lable information, such that decisions are tailored to the individual’s values and preferences. Accu-
rate estimations of one’s risk of progression to end-stage kidney disease and death with or without 
dialysis are essential for shared decision making to be effective. Formal risk prediction models can 
help, provided they are externally validated, well-calibrated and discriminative; include unam-
biguous and measureable variables; and come with readily applicable equations or scores. Reliable, 
externally validated risk prediction models for progression of chronic kidney disease to end-stage 
kidney disease or mortality in frail elderly with or without chronic kidney disease are scant. Within 
this paper, we discuss a number of promising models, highlighting both the strengths and limitations 
physicians should understand for using them judiciously, and emphasize the need for external 
validation over new development for further advancing the field.  
 




The prevalence of Chronic Kidney Dise-
ase (CKD) increases with age, but few of the 
elderly actually progress to End Stage Kidney 
Disease (ESKD) [1–5]. During the past decade 
and partly fuelled by the KDIGO classification 
of CKD, many have started questioning whe-
ther in the elderly, decreased estimated glome-
rular filtration rate (eGFR) should really be la-
belled as a "disease" at all [6]. Simultaneously, 
a tendency to start renal replacement therapy 
(RRT) at higher eGFR thresholds, has resulted 
in a spectacular increase in older people star-
ting dialysis [7, 8]. Strikingly, the higher inci-
dence of RRT in the elderly has been mirrored 
by an increasing number opting to withdraw 
from dialysis [9]. Despite large variation in 
attitudes between regions [10], the idea of con-
servative care has been gaining traction [11–
13]. As a consequence, both nephrologists and 
patients are currently struggling with how to 
approach advanced CKD.  
A thematic analysis of disease trajectory 
experiences in elderly patients diagnosed with 
CKD revealed different themes that should be 
addressed to improve the care for this popula-
tion: patients were shocked with their being la-
belled as having a serious disease, and were 
anxious about their prognosis; nephrologists 
felt uncertain about what and how to explain 
the complexity of the condition, and how to 
predict and steer future events; patients were 
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eager to discuss eventual advanced care plan-
ning and/or need for dialysis, whereas nephro-
logists felt very uncomfortable and tended to 
avoid discussing likely negative aspects about 
their future [14]. 
Counselling older people with advanced 
CKD (eGFR<45ml/min/1.73m²) requires reli-
able estimates of an individuals’ absolute pro-
bability of death within a given time frame, 
both with and without starting dialysis. Fur-
thermore, it requires accurate assessment of an 
individuals' absolute probability of progression 
to ESKD and eventual need for RRT. Predic-
ting risk of progression to ESKD needs to take 
into account the competing risk of death to pro-
vide relevant information, whereas predicting 
death is hampered by the fact that developing 
ESKD in itself is a powerful predictor for mor-
tality. Predicting progression is also challen-
ging because GFR decline may not be linear 
[15], and rapid decline may occur unpredic-
tably if associated with acute kidney injury 
[16]. This is especially true for older people 
who are at greater risk of acute kidney injury 
because of the high prevalence of frailty and 
other long-term term conditions [17]. 
First, correctly identifying patients likely 
to die early regardless of whether RRT is star-
ted, may avoid the unnecessary anxiety indu-
ced by preparing for dialysis, and the burden of 
dialysis itself. Conversely, in patients correctly 
identified as those who will reach ESKD long 
before dying, shared decisions on management, 
require counselling patients and families on 
different treatment options (haemodialysis, pe-
ritoneal dialysis, home-based vs hospital-based 
dialysis modality, conservative care), balancing 
quality versus quantity of life. Second, a robust 
method for identifying those at high risk of 
progression is necessary to focus renoprotecti-
ve therapy to those who will benefit from it. 
Last, correctly estimating risk of death after 
starting RRT may provide a more accurate per-
ception of the desirability of starting dialysis.  
Within this paper we will try to construct 
an algorithm that helps in planning the nephro-
logical care of elderly people with advanced 
CKD. We will discuss its potential use in cli-
nical shared decision making, and its potential 
pitfalls and drawbacks.  
Shared decision making 
Over the last years, shared decision ma-
king has been forwarded as an important in-
strument to improve quality of care [18]. In 
contrast to the conventional paternalistic appro-
ach to medical decision making in which the 
physician decides what is best for the patient, 
shared decision making tries to involve the opi-
nion, values and expectations of the patient in 
the process. For it to be effective, three steps 
are essential (Figure 1). The first step encom-
passes informing the patient about the different 
available options. The expected or most likely 
outcomes and eventual dangers of these dif-
ferent options should be clearly explained. In 
the setting of the elderly with advanced CKD, 
prediction of the outcomes ‘mortality’ and ‘pro-
gression to ESKD’ is prime for informing the pro-
cess of shared decision making. During the past 
decade, there have been several attempts at deve-
loping risk prediction models, combining multiple 
demographic (e.g. age, sex) and clinical characte-
ristics (e.g. medical history, physical examination 
results) to estimate individual risk of for each of 
these situations in the elderly (see below). 
Several aspects might jeopardize infor-
mation transfer. First, the correct information 
on the expected outcome of the different op-
tions might simply not be available, or might 
not be available for the specific population the 
patient belongs to (generalizability, external 
validity). This might be especially problematic 
in elderly patients with advanced CKD, as both 
elderly and patients with advanced CKD are 
mostly excluded from studies, and trials in these 
people are scant. Unfortunately, data from the ge-
neral population, or even from the elderly with-
out CKD or the non-elderly with CKD, are not 
readily translated to the elderly with CKD. Ap-
plying prognostic models developed in the ge-
neral population to elderly patients with advan-
ced CKD may result in overoptimistic progno-
sis, and pointless technical investigations and care. 
Second, the information can be transfer-
red in a biased, non-neutral way. Some treat-
ment routines are so embedded in the structure 
and paths of care that everybody accepts them 
as the only possible way, leaving no room for 
alternatives. Accordingly, information on the 
alternative options is coloured by non-verbal 
(or even verbal) signs of disapproval 
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Figure 1 – Shared decision making in steps 
 
Third, the information is often transferred 
in a way the patient does not understand. It is 
very difficult to transfer information on pro-
babilities [19] and the uncertainty surrounding 
them to lay people, and even physicians and 
healthcare professionals may struggle to under-
stand them [20]. In this era of digitalisation, it 
is becoming increasingly straightforward to 
present data in any imaginable graphical for-
mat. However, there is limited evidence on 
which presentations work best, and how these 
visualisations are processed and understood by 
the audience [21]. There is some evidence that 
graphical presentations should be adapted to 
the target audience, depending upon numeracy 
and health literacy, and digital tools can help to 
make these conversions. However, whatever 
tool or visualisation used, it reduces informa-
tion from what is already a best guess. The 
resulting situation is that we are discussing 
facts that, though objective in themselves, are 
surrounded by a great degree of uncertainty, 
leaving ample room for subjective interpreta-
tion of the indeterminacy of the future presen-
ted. As such, some patients will opt for lowers 
odds than others. Experiments in the field of 
decision making on dialysis modality highlight 
that patients tend to be strongly influenced by 
stories of other patients [22] and far less by the 
same information provided by a physician. 
Fourth, information on outcomes that mat-
ter to the patient might not be available, whereas 
ample information is provided on outcomes that 
do not matter to the patient [23]. Recently, the 
SONG project tried to establish a core outcome 
set for patients on haemodialysis [24]. SONG 
clarified that most studies use outcomes that 
are not patient relevant, whereas outcomes that 
do have value are rarely studied. In 2011, a 
comparable initiative was taken by the National 
Institute of Aging. They proposed that studies 
in this domain should focus on outcomes inclu-
ding measures of pain, fatigue, physical and 
mental functioning, social roles, daily acti-
vities, disease burden, and caregiver burden 
[25].  
A next step in the shared decision making 
process is the deliberation of the available in-
formation. In this step, the physician needs to 
explore the patients’ wishes, expectations, and 
values and elicit opinion on different potential 
scenarios. In this stage, empathy or the skill to 
view the situation through the eyes of the pa-
tient, is a necessary property for the medical 
team. The deliberation can be flawed if suffi-
cient empathy is lacking, and result in the phy-
sician’s rather than the patient’s wish is fol-
lowed. Empathy can be reduced through dis-
tance, either factual – substantial difference in 
age or different social backgrounds – or crea-
ted, e.g. by a tendency to see the patient as an 
object or a case rather than as a person with 
distinct values and experiences. Empathy can 
also be endangered by authority, which not 
only comprises the supervisor or hospital board 
expecting the patient to start dialysis, but also 
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existing guidelines, or fear for litigation. Fur-
thermore, prejudice and denial can compromise 
open and empathic discussion with the patient. 
Many physicians find it a major challenge to 
discuss death with their patients, and will the-
refore try to avoid these discussions by denying 
or minimizing risk of death [26], so that pa-
tients are presented with unrealistic perspec-
tives. The last step is the actual decision ma-
king. Studies indicate that most patients want 
to be informed about the different options avai-
lable, but that most will state in one form or 
another, that the physician should take the deci-
sion for them (doctor, what would you do). As 
discussed above, this does not imply that phy-
sicians can simply do as they please, but rather 
that they should take into account patients’ de-
sires and values, and use their clinical expertise 
to propose the solution or treatment most likely 
to result in an outcome the patient desires. This 
process requires not only empathy, but also 
insight in how available evidence is applicable 
to the particular situation of the individual pa-
tient, taking into account known comorbidities. 
It is flabbergasting to realize that for most provi-
ded guidance, there is a complete lack of ex-
ternal validity of the underlying evidence for 
most subpopulations the guideline refers to [27]. 
Risk prediction models: definition and 
assessment pitfalls 
In a model of shared decision making, 
accurate and unbiased information on the fate 
of the individual is essential.  
Risk prediction models aim to objectively 
predict the risk of a future outcome, e.g. mor-
tality or ESKD, based on a set of variables 
available at the time the prediction is made. 
Essentially, each variable is awarded a weight 
– or coefficient – and combined in a mathema-
tical rule to predict an outcome of interest. Si-
milar to weather-forecasts though, it is not be-
cause intricate models exist, that they produce 
reliable estimates of what will happen in rea-
lity.  
Evaluating the quality, generalizability 
and utility of risk prediction models poses cer-
tain challenges that are both interesting from a 
methodological point of view and crucial to un-
derstand for the clinician wanting to use such 
models for informing their clinical practice. 
Some of the methods for assessing model per-
formance can be quite daunting and lead to 
misinterpretation or overly confident conclusi-
ons around accuracy, reliability and generaliza-




Risk prediction model assessment: pitfalls and solutions 
 
Model assessment pitfalls Limitations Solution 
Model only internal validated Produces overly optimistic view of 
model performance 
External validation in cohorts 
similar to target population  
C-statistic as measure of 
discrimination 
 No practical meaning 
 No differential weighting of 
misclassification errors 
 Heavily dependent on risk factor 
distribution 
Positive predictive values 
Negative predictive values 
 
Vague description and 
dichotomized risk predictors 
Classification errors 
Information reduction and increase in 
unmeasured variability 
Clarity of description 
Layered risk predictors 
Risk scores with coefficients 
rounded to nearest integer 
Information reduction and 
unmeasured variability 
Risk calculators, apps, 
integration in electronic health 
record 
 
1/First of all, a model needs to be tested 
in a group of people that was not used to devel-
op the model, it needs to be externally vali-
dated [28]. Why is that? Well of course, deve-
loping a model means mimicking the data as 
much as reasonably possible and so, often the 
resulting model will be reasonably good at pre-
dicting whatever it is that we want it to predict. 
As a consequence, conclusions based on per-
formance measures calculated in the same co-
hort as the one that was used to develop the 
model, will necessarily produce overly optimistic 
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conclusions of a model’s accuracy [29]. Ideally, 
validation is done by investigators who were 
not involved in the model development process. 
2/The performance of a risk prediction 
model is commonly assessed by testing its ca-
libration – the agreement of observed and pre-
dicted event rates – and discrimination – the 
ability to distinguish individuals who will de-
velop the outcome of interest from those who 
will not. Investigators often use the C-statistic 
as a global measure of model discrimination, 
ranging from 0.5 (random concordance) to 1 
(perfect concordance). The C-statistic can be 
seen as the area under the curve of the receiver 
operating characteristic curve, be it with seve-
ral important limitations [29].  
For one thing, it is a single number that 
does not really have a practical interpretation. 
Sure, if it equals 1, the model is perfect, and if it 
equals 0.5, throw it in the bin; but for any number 
in between, it has no practical meaning attached 
to it. It does not convey the implications of the 
misclassification errors that can occur (predicting 
an individual who experiences an event to be at 
low risk; predicting an individual who does not 
experience an event to be at high risk) [29]. For 
that we need positive and negative predictive 
values, which do have a direct clinical meaning, 
but sadly these are seldom reported. 
Secondly, the value of the C statistic de-
pends not only on the model being assessed, 
but also on the distribution of risk factors in the 
sample to which it is applied. For example, if 
eGFR is an important risk factor, the same mo-
del can appear to perform much better when 
applied to a cohort with a wide eGFR range 
than when it is applied to a cohort with a 
narrow eGFR range. Finally, the C statistic is 
only a measure of discrimination, so it provides 
no information regarding whether the overall 
magnitude of risk is predicted accurately.  
For that we need to look at calibration 
measures, which assess how accurately the mo-
del’s predictions match overall observed event 
rates. In other words, we look at the agreement 
between what we predict and what we observe. 
Without going into detail, we can safely state 
that sadly again, calibration measures are often 
omitted [30, 31]. 
3/ For a model to be useful in practice, it 
needs to include variables that are readily avai-
lable, well-defined and measurable. Clear defi-
nitions of individual risk predictors are neces-
sary to ensure inter-rater reliability. The pre-
sence or absence of "diabetes", for example, 
can be interpreted differently by different ra-
ters. Does it apply to everyone meeting inter-
national criteria, even if transient or perfectly 
controlled with limited diet restrictions; or is it 
limited to patients treated with insulin? The 
same problem arises for many commonly used 
predictors, such as cardiovascular disease, peri-
pheral vascular disease, cancer or chronic lung 
disease: if not explicitly described how these 
categorical variables should be measured, they 
can induce substantial variation in scoring, and 
thus importantly influence model performance 
[32].  
4/ For a model to be applicable in prac-
tice, it needs to come with an actual equation 
that allows straightforward calculation of an 
individual’s absolute risk of the outcome of 
interest. To this day, researchers often still opt 
to create risk scores, which basically transform 
the model parameters to integers that can be 
summed to derive a global risk prediction for 
that individual patient. A classic example we 
are all very familiar with is the CHADS-Vasc 
score, which allocates points for age, hyperten-
sion, diabetes etc., and relates that sum to an 
absolute annual risk of stroke in atrial fibril-
lation. With smartphones being in everyone’s 
pockets and emergence of companies speciali-
zing in developing apps for risk calculation, 
there seems to be increasingly less virtue in 
doing that. Instead of simplifying models to 
allow risk calculation without computer assi-
stance, attention is probably better refocussed 
to model visualisation to boost uptake and 
efficient communication of their results [21]. 
 
Available risk prediction scoring 
systems for elderly with advanced CKD 
Progression to ESKD 
Several prospective [33–35] and retro-
spective [4, 5, 36–38] cohort studies aimed to 
develop risk prediction scores based on iden-
tified risk factors for progression to ESKD. The 
Kidney Failure Risk Equation (KFRE) initiati-
ve analysed data from Canadian adults with 
eGFR 10–59 ml/min/1.73m2 to develop the KFRE 
equation to predict the risk of ESKD at 2 and 5 
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years [38]. Using 8 variables (age, sex, eGFR, 
albuminuria, serum calcium, serum phosphate, 
serum bicarbonate, and serum albumin) this 
score proved to have good discrimination capa-
city, both in development (C statistic = 0.92) 
and in the validation cohorts (C statistic = 0.84), 
and reducing the number of variables further 
down to 4 easily available parameters (age, 
gender, eGFR and albuminuria) did not 
substantially alter the discriminative capacity 
performed similarly (C statistic = 0.91 and 0.84 
in development and validation cohorts, 
respectively) [39]. An external validation was 
carried out in a Dutch cohort with stage 3–5 
CKD, demonstrating that the scores performed 
well to predict 5-year risk (C statistic 0.89 and 
0.88, respectively) and also had a good 
calibration (difference between predicted and 
observed risk 4.0% and 7.1%, respectively). In 
an external dataset with over 700.000 patients, 
the 4-variable KFRE achieved excellent 
discrimination (pooled C statistic 0.90 at 2 
years and 0.88 at 5 years), although the KFREs 
tended to overestimate risk in some non-North 
American cohorts. Addition of a calibration 
factor improved calibration in 12/15 and 10/13 
non-North American cohorts at 2 and 5 years, 
respectively [40]. These data seem to indicate 
that the 4 variable KFRE (with the use of a 
calibration factor for non-American cohorts) is 
suitable to estimate the risk for evolution to 
ESKD in this population.  
Mortality risk in CKD  
Since 2012, two high quality systematic 
reviews, one including models predicting death 
in elderly people [41] and one predicting death 
in people with CKD [42] have been published 
on the topic. Starting from the search strategies 
of these papers, we identified 24 publications 
including 31 risk prediction models, of which 
15 models target elderly people in general [43–
55], 4 elderly people with CKD 3–5 [5, 56, 57], 
and 12 elderly people with end-stage kidney di-
sease (ESKD) [58–63]. Only three models 
were developed or validated in Western Euro-
pe. The most commonly included final predic-
tors of death were age, sex, functional status, 
heart failure, malignancy and diabetes. Altho-
ugh most models included parameters of fra-
ilty, only one model was specifically developed 
within a frail elderly patient group [43]. As a 
consequence, it would be safe to consider using 
an additional scoring system for frailty in pa-
tients with a low predicted risk for mortality by 
any of these scores.  
Another caveat is that external validation 
was mostly not available, and as far as it was, it 
was mostly done by the same investigators that 
had developed the model, and in patients very 
similar to the ones included in the development 
cohort. In addition, presence of comorbidities 
was based either on self-report or on coding 
within administrative databases. Both methods 
can induce misclassification as criteria might 
not be clear or well described. This can sub-
stantially reduce predictive performance, espe-
cially upon generalisation to patient groups 
external to the ones used for model develop-
ment. In general, model performance was mo-
derate at best, with only 1 model achieving a c-
statistic of > 0.8 [49], and confidence intervals 
were generally not provided. The Bansal risk 
prediction model predicts the absolute proba-
bility of death within five years for older pe-
ople with CKD stage 3 through 5 not yet tre-
ated with dialysis, provides measures of pre-
dictive performance and was externally valida-
ted in a large cohort of representative patients, 
except that the overwhelming majority was 
able to live independently [56]. The model has 
a reasonable calibration and model discrimina-
tion in both the development (0.72; 95% CI 
0.68 to 0.74) and validation cohort (0.69; 95% 
Cl 0.64 to 0.74). As the validation cohort might 
not be representative for cohorts containing 
frail patients, and as it has been well establi-
shed that frailty is a prevalent condition in pa-
tients with advanced CKD (eGFR<45ml/min) 
[64], it is absolutely mandatory to combine the 
Bansal score with a score for frailty when 
Bansal score is low, as in this setting mortality 
risk will be governed by frailty rather than by 
traditional risk factors. However, it has been 
advocated that frailty is an additional risk fac-
tor for mortality, on top and independent of 
other traditional risk factors [65]. As such, a 
high predicted mortality with the Bansal score 
will deliver a reliable result even in a frail 
patient.  
Mortality risk in ESKD 
One risk prediction model based on the 
REIN-registry data estimates risk of death at 
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three months in older people with ESKD star-
ting with dialysis [60]. The cohort is represen-
tative for elderly patients starting dialysis, both 
in terms of age (at least 75 years old, with one 
in five > 85 years) and in terms of comorbidity 
(heart failure 33% and peripheral vascular dise-
ase 25%). This risk prediction model includes 9 
easily available predictors: age, sex, history of 
congestive heart failure, peripheral vascular 
disease, arrhythmia, cancer, severe behavioural 
disorder, mobility and baseline serum albumin 
concentration. The rate of death in the valida-
tion cohort increased with the score, indicating 
good calibration, but discrimination was mode-
rate with a c-statistic in the internal validation 
cohort of 0.75 (95% CI: 0.74–0.76). The model 
was further externally validated in a Flemish 
cohort [39], although the investigators slightly 
modified the score. Another risk prediction score 
based on the REIN-cohort data estimates risk 
of death at six months in older people with 
ESKD starting with dialysis [59]. The model 
was further externally validated in an American 
cohort [58] although again, investigators modi-
fied the score [58]. 
Floege and co-workers also developed a 
risk prediction model predicting mortality in 
patients starting dialysis based on the Framing-
ham study model [66]. This model was than 
validated in an external cohort of the Dialysis 
Outcomes and Practices. Patterns (DOPPS), 
showing a moderate discrimination (c statistic 
of 0.68 to 0.79 depending upon geographic 
location). Although the score includes age, it 
has not been developed or validated in a cohort 
of elderly dialysis patients (mean age 64 ± 14 
years), and the cohort did also not include pe-
ritoneal dialysis patients. Furthermore, the de-
velopment cohort includes only patients who 
survived the first 3 months, whereas the vali-
dation cohort of DOPPS includes mainly pre-
valent patients. Both attributes make that the 
score is likely to be not very representative for 
the dilemma whether or not to start dialysis in 
the frail elderly, where exactly this risk of short 
term mortality during the initiation phase of 
dialysis is what needs to be predicted. 
 
Conclusions 
In conclusion, reliable, externally valida-
ted risk prediction models for progression of 
CKD to ESKD or mortality in frail elderly with 
or without CKD are necessary to inform shared 
decision making in the trajectory of the elderly 
with advanced CKD, but available models are 
scant. Physicians need to understand the limi-
tations of these models so that they can be used 
appropriately. Next to understanding the mo-
dels themselves, healthcare workers need to 
translate the available information to patients, 
and that in a way the patient can understand, 
and use the information to choose a trajectory 
of care most likely to achieve his/her goals and 
expectations, taking into account his individual 
needs. Rather than developing new models in a 
search for more sophisticated statistical models, 
we emphasize the importance of external vali-
dation by different investigators of those mo-
dels in both frail and non-frail elderly patients 
to test their performance and applicability. In 
addition, more effort must go to developing 
strategies for translating the information such 
that it becomes digestible and understandable 
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Како што стареат луѓето, хроничната буб-
режна болест станува сè почеста, но ретко дове-
дува до краен стадиум на бубрежна болест. Кога 
ќе се случи тоа, изборот помеѓу дијализа и кон-
зервативна нега може да биде застрашувачки, 
бидејќи тоа многу зависи од животниот век и 
личните очекувања од медицинската нега. Заед-
ничкото донесување одлуки подразбира соод-
ветно информирање на пациентите за нивните 
можности, и олеснување на разгледувањето на 
достапните информации, така што одлуките се 
приспособени на вредностите и преференциите 
на поединецот. Точните процени за ризикот од 
прогресија до краен стадиум на бубрежна болест 
и смрт, со или без дијализа, се суштински за да 
биде ефикасно заедничкото донесување одлука. 
Формалните модели за предвидување ризик може 
да помогнат ако се надворешно потврдени, добро 
калибрирани и дискриминативни; ако вклучуваат 
недвосмислени и мерливи променливи; и ако 
доаѓаат со применливи равенки или резултати. 
Недоволни се сигурните, надворешно потврдени 
модели за предвидување ризик од прогресија на 
хроничната бубрежна болест до краен стадиум на 
бубрежна болест или смртност кај снемоштени 
стари лица со или без хронична бубрежна болест. 
Во рамките на овој труд, разгледуваме голем број 
надежни модели, истакнувајќи ги предностите и 
ограничувањата што треба да ги разберат лека-
рите за да ги користат разумно и да ја истакнуваат 
потребата од надворешна валидација преку нов 
развој за натамошно унапредување на полето. 
 
Клучни зборови: прогноза, пропорционални модели 
на ризик, логистички модели, возрасни лица, буб-
режна инсуфициенција, хронична 
 
 
  
 
